Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hebenrun in Type 2 Diabetes Mellitus
NCT07768280Not yet recruiting
- Sponsor
- Jiangxi University of Traditional Chinese Medicine
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Jiangxi University of Traditional Chinese Medicine. Primary endpoint: Complete discontinuation rate of oral hypoglycemic drugs at 48 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07768280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768280.